2025 Q4 -tulosraportti
Vain PDF
67 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 26 168 | - | - | ||
| 300 | - | - | ||
| 3 521 | - | - | ||
| 506 | - | - | ||
| 636 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·8 t sittenPlease continue, so we can have some fun now that it's the weekend
·3 t sittenShhh, calm down little darling🥰 We others in Circio will fly high - you'll probably be left behind here🫣 Left alone, broke, cold, ashamed, and without a ticket😪😪 You know, you need to get in touch with your inner feelings. You probably need some good warm hugs🥳 Recommend those white shirts that certain institutions etc. lend out - "hug yourself shirt"👻👻 We're all cheering for you, Get well again🥰 Good night😴😴
·11 t sittenNice with weekend 🍺⚽️ But it's not often I look forward to Monday. 😅
·11 t sittenI'm also looking forward to the week. My expectations are still for an increase. I easily believe it can be a 10-20% increase for many days. If we get a good stock exchange announcement, the price can easily double and more. Very exciting time ahead now👍
·10 t sittenIt goes without saying that the share price can increase if we get good information. But information worth 2 billion mcap, well, we'll see.
·13 t sittenIt's fine to assess fair value in ordinary companies. P/E and P/B etc. But how to assess the value of Circio? It becomes much more difficult. The value is obviously what the market is willing to pay, but how to assess if the market "is wrong". Everyone understands that if we get a license agreement, the value will skyrocket. But what is fair value now. I have a friend named chatgpt.com. He thought the share issues with cash holdings contribute 1.5-2 kr per share. Risk-adjusted value of circvec based on study results 1.5-2.5 billion. Option value agreement with big pharma 0.5-1.5 billion. Fair value right now 11-12 kr. License agreement with BP with good upfront payment: 20 kr +. Take it for what it is. Have a good weekend. 😊
·8 t sittenRecommendation and 12-month price target: Hold. 12-month price target NOK 10.50 (upside approx. 26 % from today's level around NOK 8.35). Main conclusions from the analysis (max 5 sentences): Circio has a technologically strong circVec-platform with impressive preclinical data (40–50x higher expression and >6 months durability), first validation through collaboration with a top-5 global pharmaceutical player and solid financing that provides runway into 2030. The valuation is supported by rNPV-modeling of the platform and TG01, but early stage entails high clinical and technical risk – translation to disease models and humans is still unconfirmed. Recommends closely following H2 2026 milestones (disease-model efficacy and T-cell PoC) for potential re-rating; current price partly reflects optimism but is below our base case. The company represents a speculative, high-risk/high-reward opportunity within next-generation gene and cell therapy. Valuation range (low / base / high): NOK 4.00 / NOK 10.50 / NOK 18.00 per share.
·14 t sittenSometimes I wonder why there's so much shit-slinging here on the forum🤔🤔🤔 Can't we just accept that we disagree and have different strategies for our investments without badmouthing others? It doesn't really affect me or you if someone holds, sells, or buys or whatever they might do...🤔 And thanks to those of you who actually contribute with facts here🙂 Wishing everyone a nice weekend and good luck with this and other stocks. I myself believe that Circio is a good investment and I'm staying in this one🙂 P.s I'm prepared for some 💩💩💩 on this post too😂
13 t sitten13 t sittenYou are absolutely right. I myself have faced some bad comments, when trying to bring some reason into the discussions. Circio might be a really good investment, but it might also fail. We all hope for the best, not just because we can make some money here and now, but also because this could save lifes in the future - that is my opinion the biggest goal.·12 t sittenIt's such a shame that those who actually have knowledge to contribute here perhaps just skip it because of all the nonsense and rubbish in the comment section. This is clearly a risk stock, but I hope and believe that those who buy shares know about the risk. But we all make mistakes sometimes, regardless of whether new or experienced in the stock world...🙈
·15 t sittenJust to have said it, I think some here need to be reminded that clinical studies take a very long time (years). That they require enormous capital, and not least that one can constantly be met with problems regarding tolerance and effect. Good luck!
·5 t sittenCircio has no plans for clinical studies. They will out-license or be acquired and leave clinical development to big pharma. For every deal made in ‘26 and the years to come, we will see big lifts in the share price 💪 strong belief in the coming months and years! 🥳
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
67 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·8 t sittenPlease continue, so we can have some fun now that it's the weekend·3 t sittenShhh, calm down little darling🥰 We others in Circio will fly high - you'll probably be left behind here🫣 Left alone, broke, cold, ashamed, and without a ticket😪😪 You know, you need to get in touch with your inner feelings. You probably need some good warm hugs🥳 Recommend those white shirts that certain institutions etc. lend out - "hug yourself shirt"👻👻 We're all cheering for you, Get well again🥰 Good night😴😴
- ·11 t sittenNice with weekend 🍺⚽️ But it's not often I look forward to Monday. 😅·11 t sittenI'm also looking forward to the week. My expectations are still for an increase. I easily believe it can be a 10-20% increase for many days. If we get a good stock exchange announcement, the price can easily double and more. Very exciting time ahead now👍·10 t sittenIt goes without saying that the share price can increase if we get good information. But information worth 2 billion mcap, well, we'll see.
- ·13 t sittenIt's fine to assess fair value in ordinary companies. P/E and P/B etc. But how to assess the value of Circio? It becomes much more difficult. The value is obviously what the market is willing to pay, but how to assess if the market "is wrong". Everyone understands that if we get a license agreement, the value will skyrocket. But what is fair value now. I have a friend named chatgpt.com. He thought the share issues with cash holdings contribute 1.5-2 kr per share. Risk-adjusted value of circvec based on study results 1.5-2.5 billion. Option value agreement with big pharma 0.5-1.5 billion. Fair value right now 11-12 kr. License agreement with BP with good upfront payment: 20 kr +. Take it for what it is. Have a good weekend. 😊·8 t sittenRecommendation and 12-month price target: Hold. 12-month price target NOK 10.50 (upside approx. 26 % from today's level around NOK 8.35). Main conclusions from the analysis (max 5 sentences): Circio has a technologically strong circVec-platform with impressive preclinical data (40–50x higher expression and >6 months durability), first validation through collaboration with a top-5 global pharmaceutical player and solid financing that provides runway into 2030. The valuation is supported by rNPV-modeling of the platform and TG01, but early stage entails high clinical and technical risk – translation to disease models and humans is still unconfirmed. Recommends closely following H2 2026 milestones (disease-model efficacy and T-cell PoC) for potential re-rating; current price partly reflects optimism but is below our base case. The company represents a speculative, high-risk/high-reward opportunity within next-generation gene and cell therapy. Valuation range (low / base / high): NOK 4.00 / NOK 10.50 / NOK 18.00 per share.
- ·14 t sittenSometimes I wonder why there's so much shit-slinging here on the forum🤔🤔🤔 Can't we just accept that we disagree and have different strategies for our investments without badmouthing others? It doesn't really affect me or you if someone holds, sells, or buys or whatever they might do...🤔 And thanks to those of you who actually contribute with facts here🙂 Wishing everyone a nice weekend and good luck with this and other stocks. I myself believe that Circio is a good investment and I'm staying in this one🙂 P.s I'm prepared for some 💩💩💩 on this post too😂13 t sitten13 t sittenYou are absolutely right. I myself have faced some bad comments, when trying to bring some reason into the discussions. Circio might be a really good investment, but it might also fail. We all hope for the best, not just because we can make some money here and now, but also because this could save lifes in the future - that is my opinion the biggest goal.·12 t sittenIt's such a shame that those who actually have knowledge to contribute here perhaps just skip it because of all the nonsense and rubbish in the comment section. This is clearly a risk stock, but I hope and believe that those who buy shares know about the risk. But we all make mistakes sometimes, regardless of whether new or experienced in the stock world...🙈
- ·15 t sittenJust to have said it, I think some here need to be reminded that clinical studies take a very long time (years). That they require enormous capital, and not least that one can constantly be met with problems regarding tolerance and effect. Good luck!·5 t sittenCircio has no plans for clinical studies. They will out-license or be acquired and leave clinical development to big pharma. For every deal made in ‘26 and the years to come, we will see big lifts in the share price 💪 strong belief in the coming months and years! 🥳
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 26 168 | - | - | ||
| 300 | - | - | ||
| 3 521 | - | - | ||
| 506 | - | - | ||
| 636 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
67 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·8 t sittenPlease continue, so we can have some fun now that it's the weekend·3 t sittenShhh, calm down little darling🥰 We others in Circio will fly high - you'll probably be left behind here🫣 Left alone, broke, cold, ashamed, and without a ticket😪😪 You know, you need to get in touch with your inner feelings. You probably need some good warm hugs🥳 Recommend those white shirts that certain institutions etc. lend out - "hug yourself shirt"👻👻 We're all cheering for you, Get well again🥰 Good night😴😴
- ·11 t sittenNice with weekend 🍺⚽️ But it's not often I look forward to Monday. 😅·11 t sittenI'm also looking forward to the week. My expectations are still for an increase. I easily believe it can be a 10-20% increase for many days. If we get a good stock exchange announcement, the price can easily double and more. Very exciting time ahead now👍·10 t sittenIt goes without saying that the share price can increase if we get good information. But information worth 2 billion mcap, well, we'll see.
- ·13 t sittenIt's fine to assess fair value in ordinary companies. P/E and P/B etc. But how to assess the value of Circio? It becomes much more difficult. The value is obviously what the market is willing to pay, but how to assess if the market "is wrong". Everyone understands that if we get a license agreement, the value will skyrocket. But what is fair value now. I have a friend named chatgpt.com. He thought the share issues with cash holdings contribute 1.5-2 kr per share. Risk-adjusted value of circvec based on study results 1.5-2.5 billion. Option value agreement with big pharma 0.5-1.5 billion. Fair value right now 11-12 kr. License agreement with BP with good upfront payment: 20 kr +. Take it for what it is. Have a good weekend. 😊·8 t sittenRecommendation and 12-month price target: Hold. 12-month price target NOK 10.50 (upside approx. 26 % from today's level around NOK 8.35). Main conclusions from the analysis (max 5 sentences): Circio has a technologically strong circVec-platform with impressive preclinical data (40–50x higher expression and >6 months durability), first validation through collaboration with a top-5 global pharmaceutical player and solid financing that provides runway into 2030. The valuation is supported by rNPV-modeling of the platform and TG01, but early stage entails high clinical and technical risk – translation to disease models and humans is still unconfirmed. Recommends closely following H2 2026 milestones (disease-model efficacy and T-cell PoC) for potential re-rating; current price partly reflects optimism but is below our base case. The company represents a speculative, high-risk/high-reward opportunity within next-generation gene and cell therapy. Valuation range (low / base / high): NOK 4.00 / NOK 10.50 / NOK 18.00 per share.
- ·14 t sittenSometimes I wonder why there's so much shit-slinging here on the forum🤔🤔🤔 Can't we just accept that we disagree and have different strategies for our investments without badmouthing others? It doesn't really affect me or you if someone holds, sells, or buys or whatever they might do...🤔 And thanks to those of you who actually contribute with facts here🙂 Wishing everyone a nice weekend and good luck with this and other stocks. I myself believe that Circio is a good investment and I'm staying in this one🙂 P.s I'm prepared for some 💩💩💩 on this post too😂13 t sitten13 t sittenYou are absolutely right. I myself have faced some bad comments, when trying to bring some reason into the discussions. Circio might be a really good investment, but it might also fail. We all hope for the best, not just because we can make some money here and now, but also because this could save lifes in the future - that is my opinion the biggest goal.·12 t sittenIt's such a shame that those who actually have knowledge to contribute here perhaps just skip it because of all the nonsense and rubbish in the comment section. This is clearly a risk stock, but I hope and believe that those who buy shares know about the risk. But we all make mistakes sometimes, regardless of whether new or experienced in the stock world...🙈
- ·15 t sittenJust to have said it, I think some here need to be reminded that clinical studies take a very long time (years). That they require enormous capital, and not least that one can constantly be met with problems regarding tolerance and effect. Good luck!·5 t sittenCircio has no plans for clinical studies. They will out-license or be acquired and leave clinical development to big pharma. For every deal made in ‘26 and the years to come, we will see big lifts in the share price 💪 strong belief in the coming months and years! 🥳
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 26 168 | - | - | ||
| 300 | - | - | ||
| 3 521 | - | - | ||
| 506 | - | - | ||
| 636 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt